[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100593988":3},{"organization":4,"armGroups":7,"interventions":24,"overallOfficials":34,"centralContacts":39,"locations":49,"responsibleParty":69,"collaborators":72,"id":76,"slug":77,"hasResults":78,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":30,"eligibilityCriteria":82,"healthyVolunteers":78,"sex":83,"minAge":84,"maxAge":30,"enrollmentInfo":85,"targetDuration":30,"studyType":88,"phases":89,"briefSummary":91,"conditions":92,"keywords":94,"overallStatus":51,"whyStopped":30,"lastUpdateSubmitDate":101,"lastUpdatePostDateStruct":102,"startDateStruct":105,"completionDateStruct":107,"leadSponsor":109,"locationsCount":110},{"fullName":5,"class":6},"Brigham and Women's Hospital","OTHER",[8,14,18],{"label":9,"type":10,"description":11,"interventionNames":12},"NMN (MIB-626) for 7 days preoperatively, on day of surgery, and for 4 days postoperatively","EXPERIMENTAL","NMN (MIB-626) 1000 mg PO daily, for 7 days preoperatively, on day of surgery, and for 4 days postoperatively",[13],"Drug: MIB-626",{"label":15,"type":10,"description":16,"interventionNames":17},"NMN administered for 2 days preoperatively, on the day of surgery, and for 4 days postoperatively","NMN (MIB-626) 1,000 mg PO twice daily, administered for 2 days preoperatively, on the day of surgery, and for 4 days postoperatively",[13],{"label":19,"type":20,"description":21,"interventionNames":22},"Placebo","PLACEBO_COMPARATOR","Placebo administered for 7 days preoperatively, on the day of surgery, and for 4 days postoperatively",[23],"Other: Placebo",[25,31],{"type":26,"name":27,"description":28,"armGroupLabels":29,"otherNames":30},"DRUG","MIB-626","An orally-administered stable crystalline tablet formulation of NMN",[9,15],null,{"type":6,"name":19,"description":32,"armGroupLabels":33,"otherNames":30},"matching placebo tablets",[19],[35],{"name":36,"affiliation":37,"role":38},"Shalender Bhasin, MB, BS","Brigham and Women's Hosptial","PRINCIPAL_INVESTIGATOR",[40,45],{"name":41,"role":42,"phone":43,"phoneExt":30,"email":44},"Shalender Bhasin, MB,BS","CONTACT","617-525-9150","sbhasin@bwh.harvard.edu",{"name":46,"role":42,"phone":47,"phoneExt":30,"email":48},"David E Leaf, MD","617-732-5951","deleaf@bwh.harvard.edu",[50],{"facility":5,"status":51,"city":52,"state":53,"zip":54,"country":55,"countryCode":56,"cosmosGeoPoint":57,"geoPoint":62,"contacts":63},"RECRUITING","Boston","Massachusetts","02115","United States","US",{"type":58,"coordinates":59},"Point",[60,61],-71.05977,42.35843,{"lat":61,"lon":60},[64,65],{"name":46,"role":42,"phone":47,"phoneExt":30,"email":48},{"name":66,"role":42,"phone":67,"phoneExt":30,"email":68},"Nancy Latham, PhD","6179999195","nklatham@bwh.harvard.edu",{"type":38,"investigatorFullName":70,"investigatorTitle":71,"investigatorAffiliation":5,"oldNameTitle":30,"oldOrganization":30},"Shalendar Bhasin, MD","Principal Investigator",[73],{"name":74,"class":75},"National Institute on Aging (NIA)","NIH","100593988","phase-2-nicotinamide-mononucleotide-in-patients-undergoing-cabg-surgery-100593988",false,"NCT07013591","Nicotinamide Mononucleotide in Patients Undergoing CABG Surgery","Randomized Clinical Trial of β Nicotinamide Mononucleotide in Patients Undergoing CABG Surgery","Inclusion Criteria:\n\n1. Age ≥18 years\n2. Scheduled to undergo elective isolated CABG surgery with cardiopulmonary bypass (CPB)\n3. At increased risk of postoperative complications based on ≥1 of the following:\n\n   1. Age ≥65 years\n   2. eGFR \\\u003C45 ml\u002Fmin\u002F1.73m2\n   3. Documented history of congestive heart failure or left ventricular ejection fraction (LVEF) ≤40% within 6 months before surgery\n   4. Diabetes mellitus and urine albumin-to-creatinine ratio \\>30 mg\u002Fg creatinine\n   5. Peripheral arterial disease\n   6. Anemia, defined as hemoglobin \\\u003C10 g\u002Fdl\n   7. Prior cardiac surgery\n\nExclusion Criteria:\n\n1. Any of the following laboratory abnormalities at the time of screening:\n\n   1. ALT \\>3-fold the upper limit of normal\n   2. eGFR \\\u003C30 ml\u002Fmin\u002F1.73m2 or ESKD on dialysis\n   3. Hemoglobin \\\u003C8 g\u002Fdl\n2. History of gastric bypass or malabsorption\n3. Active alcohol or illicit substance use in the prior 6 months\n4. Participation in an investigational trial to evaluate pharmaceuticals or biologics within the past 3 months or 5 half-lives, whichever is shorter\n5. Pregnant or breast-feeding\n6. Unwillingness to use contraception while taking study drug and for 8 weeks after the last dose for women of reproductive age or non-sterilized male participants who are sexually active with a female partner of childbearing potential\n7. Current use of niacin \\>100 mg\u002Fday or NMN, nicotinamide, or nicotinamide riboside at any dose\n8. Conflict with other research studies\n9. Any condition which, in the judgement of the investigator, might increase the risk to the participant","ALL","18 Years",{"count":86,"type":87},90,"ESTIMATED","INTERVENTIONAL",[90],"PHASE2","The investigators will perform a phase 2a, randomized, double-blind, placebo-controlled clinical trial in adult patients undergoing elective coronary artery bypass grafting (CABG) surgery to investigate the effects of oral nicotinamide mononucleotide (NMN) administration on myocardial NAD+ concentrations and on postoperative markers of myocardial and kidney injury.",[93],"Coronary Artery Bypass Graft",[95,96,97,98,99,100],"coronary artery bypass graft","cardiac surgery","cardiopulmonary bypass","nicotinamide","NMN","acute kidney injury","2026-06-24",{"date":103,"type":104},"2026-06-26","ACTUAL",{"date":106,"type":104},"2026-06-10",{"date":108,"type":87},"2029-01-01",{"name":5,"class":6},1]